Document is current
Any future updates will be listed below
-
Authors
Conduit, Sarah E. https://orcid.org/0000-0002-5075-8851
Vasan, Neil https://orcid.org/0000-0003-1779-484X
Brown, Jennifer R. https://orcid.org/0000-0003-2040-4961
Perry, Matthew W. D. https://orcid.org/0000-0002-9799-0746
Vanhaesebroeck, Bart https://orcid.org/0000-0002-7074-3673
- License Information
-
More Information
Article History
Accepted: 29 January 2026
First Online: 30 March 2026
Competing interests
: B.V. is a consultant for iOnctura (Geneva, Switzerland); a shareholder of Open Orphan and Poolbeg Pharma (Dublin, Ireland); and a director of S&B Scientific. J.R.B. has served as a consultant for Abbvie, Acerta/AstraZeneca, Alloplex Biotherapeutics, BeiGene, Bristol-Myers Squibb, EcoR1, Galapagos NV, Genentech/Roche, Grifols Worldwide Operations, InnoCare Pharma Inc, Loxo/Lilly, Magnet Biomedicine, Merck and Pharmacyclics; received research funding from BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, Nagoon Therapeutics and TG Therapeutics; and serves on the Data Safety Monitoring Board for Grifols Therapeutics. N.V. reports consultin g for Apertor Therapeutics, Avenzo Therapeutics, GLG, Guidepoint Global, Reactive Biosciences and Scorpion Therapeutics; royalties from Wolters Kluwer; and stock in Reactive Biosciences, Heligenics, Inc. M.W.D.P. is an employee of and stockholder in AstraZeneca. S.E.C. has no interests to declare.
